Exclusive interview: Dr David Rabin of Apollo Neuro

David Rabin - Apollo Neuro

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

We talk about stress management, HRV’s effect on healthspan and new services with the co-founder of Apollo Neuro.

As I write this intro my Apollo Neuro device is set to ‘Clear and Focused’ for 60 mins at a 65% intensity. My day is full of distractions and within a few days of my interview with Apollo Neuro’s Dr David Rabin I’ve become hooked!

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Phil Newman

Editor-in-Chief

Phil is Editor-in-Chief Longevity.Technology and founder of First Longevity which brings together international investors and Longevity start-ups.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Windward Bio raises $251m with Sanofi buying in

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE